Cargando…
A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
OBJECTIVE: To examine the effects of naltrexone/bupropion (NB) combination therapy on weight and weight-related risk factors in overweight and obese participants. DESIGN AND METHODS: CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2))...
Autores principales: | Apovian, Caroline M, Aronne, Louis, Rubino, Domenica, Still, Christopher, Wyatt, Holly, Burns, Colleen, Kim, Dennis, Dunayevich, Eduardo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739931/ https://www.ncbi.nlm.nih.gov/pubmed/23408728 http://dx.doi.org/10.1002/oby.20309 |
Ejemplares similares
-
Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012) -
Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016) -
A Natural Fiber Complex Reduces Body Weight in the Overweight and Obese: A Double-Blind, Randomized, Placebo-Controlled Study
por: Grube, Barbara, et al.
Publicado: (2013) -
Arterial Stiffness, Lifestyle Intervention and a Low-Calorie Diet in Morbidly Obese Patients—A Nonrandomized Clinical Trial
por: Nordstrand, N, et al.
Publicado: (2013) -
Calorie Anticipation Alters Food Intake After Low-Caloric but Not High-Caloric Preloads
por: Hogenkamp, PS, et al.
Publicado: (2013)